Delivery Order SPE2DB20D1100-SPE2DB24FD2S2

Award Date 8/14/24
Potential Completion Date 8/15/24
Potential Value $3.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $3,844.55, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of November 26, 2024 and is a Firm Fixed Price arrangement. It is not designated as a set-aside contract. AmerisourceBergen holds a significant...
This federal contract award, valued at $1,891.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 72 MCG CAPSULE UU 30S, a pharmaceutical product, with a performance period extending through May 12, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,017.18 firm fixed-price delivery order is for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of March 3, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award, valued at $1,558.54, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of September 20, 2023 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award, valued at $1,654.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE, a pharmaceutical product. The contract has an ultimate completion date of December 30, 2024, and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
This federal contract award, valued at $2,487.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LINZESS 290 MCG CAPSULE UU 30S, a medical product, with a completion date of May 9, 2023. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,150.08 firm fixed price delivery order is for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of February 19, 2025 and was awarded on February 18, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This federal contract award, valued at $1,587.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE UU 30S, a pharmaceutical product. The award is a delivery order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award, valued at $1,260.32, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for the supply of LINZESS 145 MCG CAPSULE, a medication, with a performance period ending on April 18, 2025. The contract is a firm fixed-price, non-set-aside award, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award, valued at $11,175.65, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product, to support federal healthcare programs. The contract is a Delivery Order type with a Firm Fixed Price pricing structure, and an ultimate completion date of February 26, 2025. This award is not...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FD2S2
    Delivery Order

This federal contract award, valued at $3,239.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the delivery of LINZESS 145 MCG CAPSULE UU 30S. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 and running through December 2025. AmerisourceBergen, one of the largest pharmaceutical distributors in the U.S., will supply these essential pharmaceutical products to support military treatment programs and facilities worldwide. This contract does not have a set-aside designation and has an ultimate completion date of August 15, 2024.

Generated 11/13/24, 9:21 AM